IP Library Granted Patent US 9,394,233
Granted Patent B2
US 9,394,233 · App. 13/782,202 · Granted Jul 19, 2016

ROS-activated compounds as selective anti-cancer therapeutics

Inventors: Edward J. Merino (Cincinnati, OH); James C. Mulloy (Cincinnati, OH); Guorui Li (Baltimore, MD); Tiffany Bell-Horwath (Cheviot, OH)
Assignees: Cincinnati Children's Hospital Medical Center; University of Cincinnati
C07C217/20A61K31/138A61K31/145A61K31/167A61K31/196A61K31/215A61K31/216A61K31/451A61K45/06C07C217/84C07C229/42C07C233/25C07C237/04C07C237/08C07C321/28C07C323/25C07D295/096
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,394,233
App. No.
13/782,202
Granted
Jul 19, 2016
Kind
B2
Abstract

Provided are compounds according to the following Formula I: The Formula I compounds are activated in the presence of reactive oxygen species (ROS) and are therefore selective anti-cancer therapeutics for cancers associated with elevated ROS. Also provided are methods and pharmaceutical compositions for treating cancers associated with increased ROS.

Claims (24)

1. A compound according to Formula I:

wherein:

R 1 and R 2 are each independently selected from the group consisting of substituted or unsubstituted or branched alkyl and unsubstituted aryl wherein said alkyl and aryl optionally comprise one or more heteroatoms;

R 3 is selected from the group consisting of OH, NHC(O)CH 3 , piperidine and OC(O)CH 3 ; and n is 1-5,

wherein at least one of R 1 and R 2 is aryl.

2. The compound according to claim 1 , wherein alkyl substitutions are selected from the group consisting of alkoxyl, halo, OH, CN, carboxyl, carboxyl ester, and substituted or unsubstituted alkyl.

3. The compound according to claim 1 , wherein R 1 is alkyl when R 2 is aryl, and wherein R 2 is alkyl when R 1 is aryl.

4. The compound according to claim 1 , wherein R 1 and R 2 are each independently selected from the group consisting of substituted or unsubstituted C 1 -C 8 alkyl and unsubstituted phenyl; and R 3 is OH.

5. The compound according to claim 1 , wherein the compound is

6. A pharmaceutical composition for the treatment of a cancer associated with elevated ROS comprising:

(a) a therapeutically effective amount of a compound according to claim 1 ; and

(b) a pharmaceutically-acceptable carrier.

7. A compound selected from the group consisting of:

4-(2-(methyl(phenyl)amino)ethoxy)phenol;

4-(2-(ethyl(phenyl)amino)ethoxy)phenol;

4-(2-(isopropyl(phenyl)amino)ethoxy)phenol;

4-(3-(methyl(phenyl)amino)propoxy)phenol;

4-(3-(ethyl(phenyl)amino)propoxy)phenol;

4-(4-(methyl(phenyl)amino)butoxy)phenol;

4-(4-(ethyl(phenyl)amino)butoxy)phenol;

4-(5-(methyl(phenyl)amino)pentyloxy)phenol;

4-((5-(methyl(phenyl)amino)pentyl)oxy)phenol;

4,4′-(2,2′-(phenylazanediyl)bis(ethane-2,1-diyl)bis(oxy))diphenol; and

(((phenylazanediyl)bis(ethane-2,1-diyl))bis(oxy))bis(4,1-phenylene) diacetate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2013
From: MERINO, EDWARD J.; BELL-HORWATH, TIFFANY; LI, GUORUI
To: UNIVERSITY OF CINCINNATI
Reel/Frame 030038/0227 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2013
From: MULLOY, JAMES C.
To: CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER
Reel/Frame 030038/0346 →
Continuity (2)
Provisional Application 61605515 · Mar 1, 2012
Related Publication 20130230542A1 · Sep 5, 2013